子宫颈癌诊断市场 - 全球产业规模、份额、趋势、机会和预测，按检测类型、最终用户、地区和竞争细分，2020-2030 年预测

2024 年全球子宫颈癌诊断市场价值为 82.7 亿美元，预计到 2030 年将达到 118.9 亿美元，预测期内复合年增长率为 6.24%。由于对筛检和诊断测试的需求增加，中年女性子宫颈癌发生率的上升预计将在未来几年推动市场成长。根据世界卫生组织的出版物，子宫颈癌是全球女性中第四大常见癌症。此外，根据美国癌症协会2023年的资料，美国预计将诊断出约13,960例侵袭性子宫颈癌，导致约4,310名女性死亡。

主要市场驱动因素

提高认识和教育

主要市场挑战

医疗不平等

主要市场趋势

分子诊断革命

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第五章：全球子宫颈癌诊断市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依检查类型（巴氏抹片检查、HPV 检测、阴道镜检查、子宫颈切片、膀胱镜检查）
  • 按最终使用者（医院和诊所、诊断实验室、其他）
  • 按地区
  • 按公司分类（2024）
• 产品市场图
  • 按测试类型
  • 按最终用途
  • 按地区

第 6 章：北美子宫颈癌诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 加拿大
  • 墨西哥

第 7 章：欧洲子宫颈癌诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 英国
  • 法国
  • 义大利
  • 西班牙

第 8 章：亚太地区子宫颈癌诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 日本
  • 印度
  • 澳洲
  • 韩国

第 9 章：南美洲子宫颈癌诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲子宫颈癌诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 科威特

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 合併与收购
• 产品发布

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Abbott Laboratories
• Thermo Fisher Scientific Inc
• Becton Dickinson and Company
• Hologic Inc
• CooperSurgical Inc
• Siemens Healthineers AG
• Quigan NV
• F. Hoffmann-La Roche Ltd
• Oncgnostics GmbH
• Quest Diagnostics

第 15 章：策略建议

第16章调查会社について・免责事项

Global Cervical Cancer Diagnostic Market was valued at USD 8.27 billion in 2024 and is expected to reach USD 11.89 billion by 2030 with a CAGR of 6.24% during the forecast period. The rise in cervical cancer rates among women in the middle age bracket is anticipated to drive market growth in the coming years due to the increased demand for screening and diagnostic tests. According to the World Health Organization's publications, cervical cancer is ranked as the fourth most prevalent cancer among women worldwide. Additionally, according to data from the American Cancer Society in 2023, it is estimated that approximately 13,960 cases of invasive cervical cancer will be diagnosed, resulting in approximately 4,310 female fatalities in the United States.

Key Market Drivers

Rising Awareness and Education

Cervical cancer is a formidable global health challenge, but increasing awareness and education are proving to be powerful catalysts for growth in the Global Cervical Cancer Diagnostic Market. The recognition of the importance of early detection and regular screenings is essential for reducing the burden of this disease. Awareness campaigns, educational programs, and advocacy efforts have been instrumental in empowering women with knowledge about cervical cancer and its prevention. These initiatives disseminate information about the disease, its risk factors, and the significance of regular screenings. As women become more informed, they are more likely to take proactive steps toward their health, including undergoing cervical cancer diagnostics.

Awareness and education campaigns stress the importance of early detection. Women who understand the benefits of regular screenings are more likely to schedule appointments with healthcare providers. This increased demand for screening services directly contributes to the growth of the cervical cancer diagnostic market. Cervical cancer screenings, such as Pap smears, can be intimidating for many women due to fear or discomfort. However, informed women are more likely to overcome these fears, knowing that early detection can be life-saving. Reducing the stigma and fear associated with cervical cancer diagnostics encourages more women to seek these services, further boosting market growth.

Key Market Challenges

Healthcare Inequity

Healthcare disparities exist in many parts of the world, and cervical cancer diagnostic services are not exempt from these inequalities. Women in marginalized communities often face barriers such as limited financial resources, lack of transportation, and inadequate healthcare infrastructure, which restrict their access to screening services.

Key Market Trends

Molecular Diagnostics Revolution

Molecular diagnostic techniques, including nucleic acid testing, have gained prominence in cervical cancer diagnosis. These methods offer increased sensitivity and specificity in detecting human papillomavirus (HPV) infections and identifying specific viral strains associated with cervical cancer. The trend is moving towards molecular testing becoming a standard procedure in cervical cancer screening, enabling more precise diagnoses.

Key Market Players

• Abbott Laboratories
• Thermo Fisher Scientific Inc
• Becton Dickinson and Company
• Hologic Inc
• CooperSurgical Inc
• Siemens Healthineers AG
• Quigan NV
• F. Hoffmann-La Roche Ltd
• Oncgnostics GmbH
• Quest Diagnostics

Report Scope:

In this report, the Global Cervical Cancer Diagnostic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cervical Cancer Diagnostic Market, By Test Type:

• Pap testing
• HPV testing
• Colposcopy
• Cervical biopsies
• Cystoscopy

Cervical Cancer Diagnostic Market, By End User:

• Hospitals & Clinics
• Diagnostic Laboratories
• Others

Cervical Cancer Diagnostic Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cervical Cancer Diagnostic Market.

Available Customizations:

Global Cervical Cancer Diagnostic market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cervical Cancer Diagnostic Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Pap testing, HPV testing, Colposcopy, Cervical biopsies, Cystoscopy)
  • 5.2.2. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Product Market Map
  • 5.3.1. By Test Type
  • 5.3.2. By End Use
  • 5.3.3. By Region

6. North America Cervical Cancer Diagnostic Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type (Pap testing, HPV testing, Colposcopy, Cervical biopsies, Cystoscopy)
  • 6.2.2. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cervical Cancer Diagnostic Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By End Use
  • 6.3.2. Canada Cervical Cancer Diagnostic Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By End Use
  • 6.3.3. Mexico Cervical Cancer Diagnostic Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By End Use

7. Europe Cervical Cancer Diagnostic Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type (Pap testing, HPV testing, Colposcopy, Cervical biopsies, Cystoscopy)
  • 7.2.2. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cervical Cancer Diagnostic Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By End Use
  • 7.3.2. United Kingdom Cervical Cancer Diagnostic Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By End Use
  • 7.3.3. France Cervical Cancer Diagnostic Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By End Use
  • 7.3.4. Italy Cervical Cancer Diagnostic Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By End Use
  • 7.3.5. Spain Cervical Cancer Diagnostic Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By End Use

8. Asia-Pacific Cervical Cancer Diagnostic Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type (Pap testing, HPV testing, Colposcopy, Cervical biopsies, Cystoscopy)
  • 8.2.2. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Cervical Cancer Diagnostic Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By End Use
  • 8.3.2. Japan Cervical Cancer Diagnostic Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By End Use
  • 8.3.3. India Cervical Cancer Diagnostic Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By End Use
  • 8.3.4. Australia Cervical Cancer Diagnostic Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By End Use
  • 8.3.5. South Korea Cervical Cancer Diagnostic Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By End Use

9. South America Cervical Cancer Diagnostic Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type (Pap testing, HPV testing, Colposcopy, Cervical biopsies, Cystoscopy)
  • 9.2.2. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Cervical Cancer Diagnostic Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By End Use
  • 9.3.2. Argentina Cervical Cancer Diagnostic Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By End Use
  • 9.3.3. Colombia Cervical Cancer Diagnostic Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By End Use

10. Middle East and Africa Cervical Cancer Diagnostic Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type (Pap testing, HPV testing, Colposcopy, Cervical biopsies, Cystoscopy)
  • 10.2.2. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Cervical Cancer Diagnostic Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By End Use
  • 10.3.2. Saudi Arabia Cervical Cancer Diagnostic Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By End Use
  • 10.3.3. UAE Cervical Cancer Diagnostic Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By End Use
  • 10.3.4. Kuwait Cervical Cancer Diagnostic Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Test Type
      • 10.3.4.2.2. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Abbott Laboratories
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.2. Product Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Thermo Fisher Scientific Inc
• 14.3. Becton Dickinson and Company
• 14.4. Hologic Inc
• 14.5. CooperSurgical Inc
• 14.6. Siemens Healthineers AG
• 14.7. Quigan NV
• 14.8. F. Hoffmann-La Roche Ltd
• 14.9. Oncgnostics GmbH
• 14.10. Quest Diagnostics

15. Strategic Recommendations

16. About Us & Disclaimer